NTRAClinical Trials•businesswire•
Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
Sentiment:Positive (65)
Summary
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, taking place September 6 - 9 in Barcelona, Spain. The presentations underscore the strong clinical utility of Signatera in lung cancer. An analysis of early-stage, resectable non-small cell lung cancer (NSCLC) patients will be
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 25, 2025 by businesswire